MDxHealth, Maastricht University Expand Cancer Dx Development Collaboration

NEW YORK (GenomeWeb) – MDxHealth announced today that it has signed an expansion of its partnership with Maastricht University to develop genetic and epigenetic cancer diagnostics.

Under the terms of the multiyear deal, MDxHealth will collaborate with Maastricht’s Faculty of Health, Medicine, and Life Sciences institute and its School for Oncology and Developmental Biology to develop genetic and epigenetic assays for diagnosing, staging, and treating cancer patients.

The company said that the assays will be designed for sample in/result out-based platforms, and that technology developed through the alliance will be applied to its current and future liquid biopsy tests including the recently launched SelectMDx prostate cancer test.

Additional terms were not disclosed.

Be the first to comment

Leave a Reply

Your email address will not be published.


*